I’ve been looking at it and I’m curious how people view it
In Q2 2026 Teva did about $4.1B in revenue and generated $622M in free cash flow. Its newer drugs also seem to be becoming a much better selling , AUSTEDO, AJOVY and UZEDY.
I like is that it’s improving cash generation and growth of the branded portfolio. What worries me is the debt net debt is still around $12.9B and whether the turnaround is already mostly reflected in the stock price.
. The company seems to be in a much better position than it was a few years ago, but I’m wondering how much of that improvement is already priced in.
For anyone following TEVA closely? Do you still see meaningful upside from here, or do you think the stock has already had most of its recovery?
Also what do you guys think about the new generic drug tariff trump is taking about?
I’ve invested in the past when their past ceo was promising to deal with the debt and ended up a bag holder till I sold .